TP53 and esophageal squamous cell carcinoma: WGCNA and network pharmacology were used in this study to investigate the anti-ESCC mechanism of RR and molecular docking technology, and in vitro, experimental verification proved that RR could inhibit the proliferation of ESCC by affecting the P53 signaling pathway and cell cycle pathway through multiple targets.